Stay updated on Amifampridine in MuSK-MG Clinical Trial
Sign up to get notified when there's something new on the Amifampridine in MuSK-MG Clinical Trial page.

Latest updates to the Amifampridine in MuSK-MG Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now displays the completed Phase 3 study of amifampridine phosphate for myasthenia gravis, including its design, eligibility criteria, locations, outcome measures, and study documents.SummaryDifference48%

- Check15 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0; the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer site revision changes from v3.7.0 to v3.7.1, while the study page continues to show a 403 error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the usual study record content and preventing access to the study details.SummaryDifference18%

Stay in the know with updates to Amifampridine in MuSK-MG Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amifampridine in MuSK-MG Clinical Trial page.